(3-fluoro-2-methyl-phenyl)-methyl-amine | 881848-76-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-fluoro-2-methyl-phenyl)-methyl-amine
• 英文别名: 3-Fluoro-2,N-dimethylaniline；3-fluoro-N,2-dimethylaniline
• CAS: 881848-76-6
• 化学式: C₈H₁₀FN
• 分子量: 139.173
• InChiKey: BIZQGLCQKSJCKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES
  申请人：Yamamoto Keisuke

  公开号：US20100256134A1

  公开（公告）日：2010-10-07

  Provided is an agent for the prevention and/or treatment of a skin disease containing, as an active ingredient, a pyrazolopyrimidine derivative represented by the formula (I) (wherein each symbol is as defined in the specification), or a pharmacologically acceptable salt thereof, and the like.

  提供了一种用于预防和/或治疗皮肤疾病的药剂，其中包含一种以式(I)表示的吡唑并嘧啶衍生物作为活性成分，其中每个符号如规范中所定义，或其药理学上可接受的盐等。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：KYOWA HAKKO KIRIN CO., LTD.

  公开号：US20150299214A1

  公开（公告）日：2015-10-22

  The present invention provides a heterocyclic compound represented by the following formula (I), wherein X A represents CH and the like, R 1 represents cycloalkyl optionally having substituent(s) and the like, L represents a bond and the like, Y A represents —NH— and the like, R 2 represents a hydrogen atom and the like, R 3A represents the following formula (R 3A -1) (wherein, R 3 represents hydroxy and the like) and the like, and R 4A represents the following formula (R 4A -1) (wherein, R 4 and R 5 are the same or different and each represents a hydrogen atom and the like) and the like, or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases and the like, and the like.

  本发明提供一种杂环化合物，其化学式表示为（I），其中XA代表CH等，R1代表环烷基，可选地具有取代基等，L代表键等，YA代表—NH—等，R2代表氢原子等，R3A代表下式（R3A-1）（其中，R3代表羟基等）等，R4A代表下式（R4A-1）（其中，R4和R5相同或不同，且每个代表氢原子等）等，或其药学上可接受的盐，其作为预防和/或治疗皮肤疾病等的药物具有用途。
• AGENT FOR PREVENTING AND/OR TREATING OCULAR INFLAMMATORY DISEASE
  申请人：KYOWA HAKKO KIRIN CO., LTD.

  公开号：US20160008362A1

  公开（公告）日：2016-01-14

  The invention provides a method for prophylaxis and/or treatment of an ocular inflammatory disease comprising administering an effective amount of a pyrazolopyrimidine compound represented by formula (I), wherein R 1 represents —NR 1a R 1b (wherein R 1a and R 1b are the same or different and each represents a hydrogen atom and the like), and the like, R 2 represents the formula (R 2 −1) [wherein k and m represent each an integer of 0-2, n represents an integer of 0-2, L represents a single bond and the like, R 5 represents a halogen and the like, R 6 represents aryl and the like, X represents —CR 8 (wherein R 8 represents a hydrogen atom and the like), and the like, R 7 represents a hydrogen atom, and the like, and the like, R 3 represents —SO 2 R 13 (wherein R 13 represents lower alkoxy and the like), and the like, and R 4 represents a hydrogen atom and the like, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种预防和/或治疗眼部炎症性疾病的方法，包括给予式(I)所表示的吡唑嘧啶化合物的有效量，其中R1表示—NR1aR1b（其中R1a和R1b相同或不同，每个表示氢原子等），R2表示式（R2-1）[其中k和m分别表示0-2的整数，n表示0-2的整数，L表示单键等，R5表示卤素等，R6表示芳基等，X表示—CR8（其中R8表示氢原子等），R7表示氢原子等，R3表示—SO2R13（其中R13表示低烷氧基等），R4表示氢原子等，或其药学上可接受的盐。
• PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR
  申请人：Medshine Discovery Inc.

  公开号：EP3741756A1

  公开（公告）日：2020-11-25

  Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

  本发明提供了一类 KRAS G12C 缄默素抑制剂，尤其涉及由式（I）代表的化合物、其异构体及其药学上可接受的盐。
• Hepatitis B antiviral agents
  申请人：Novira Therapeutics, Inc.

  公开号：US10196376B2

  公开（公告）日：2019-02-05

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

  本发明包括一种在有需要的个体中抑制、抑制或预防 HBV 感染的方法，包括向该个体施用治疗有效量的至少一种本发明化合物。